ライフサイエンスコーパス: smokeless

1 they have been marketed as a cheaper, safer smokeless alternative to traditional cigarettes and a po

2 l prevalence of current tobacco use (smoked, smokeless, and any tobacco use) among 6729 HIV-positive

3 rs, such as alcohol and tobacco (smoking and smokeless), but dietary factors and the existence of gen

4 The smokeless cigarette, Eclipse, has comparable ROS with ci

5 , respectively), followed by smoky coal, and smokeless coal (GM:148 and 115 mug/m(3), respectively).

6 6 times higher when burning smoky coal than smokeless coal and varied by up to a factor of 3 between

7 or users of smoky coal, compared to users of smokeless coal and wood.

8 nwei and Fuyuan females who used smoky coal, smokeless coal, or wood and 10 local controls who used e

9 in health evaluations is usually compared to smokeless coal--an anthracite coal available in some par

10 solid sorbent traps from the headspace of a smokeless gunpowder sample.

11 itive, and rapid method for the detection of smokeless powder components, from five different types o

12 ts resulted in perfect classification of the smokeless powder with respect to manufacturer.

13 ESI FTICR mass spectrometry of smokeless powder, TNT, and Powermite resolves and identi

14 rotoluene (TNT), and low explosives (several smokeless powders) resulting in the detection of 26-35 n

15 31-2.59], respectively), attempt to purchase smokeless tobacco (adjusted OR, 2.16 [95% CI, 1.90-2.45]

16 rrent prevalence, 15.7% vs 3.9%; P<.001) and smokeless tobacco (current prevalence, 8.7% vs 0.4%; P<.

17 s to determine whether an aqueous extract of smokeless tobacco (moist snuff) increases clearance of m

18 the validity of self-reported information on smokeless tobacco (SLT) use is uncertain.

19 on (EU) legislation bans the sale of snus, a smokeless tobacco (SLT) which is considerably less harmf

20 Despite the reported effects of smokeless tobacco (ST) on the periodontium and high prev

21 mucosal lesions frequently occur at sites of smokeless tobacco (ST) placement.

22 favoured by most smokers (82%) overall, but smokeless tobacco and bidis were commonly used in India

23 Furthermore, combined use of smokeless tobacco and cigarettes did not increase overal

24 cancer mortality rate among combined users (smokeless tobacco and cigarettes), based on the rates fo

25 al. describe the association between use of smokeless tobacco and head and neck cancer in 11 US case

26 Few or no associations between each type of smokeless tobacco and HNC were observed among ever cigar

27 e exposed organotypic cultures for 3 days to smokeless tobacco aqueous extracts and determined the ch

28 The FDA thus concluded that cigarettes and smokeless tobacco are subject to FDA jurisdiction becaus

29 Current use of smokeless tobacco at baseline was associated with 1.27-f

30 correlated with number of tins or pouches of smokeless tobacco consumed.

31 We hypothesized that smokeless tobacco could modulate the growth of keratinoc

32 A determined that nicotine in cigarettes and smokeless tobacco does "affect the structure or any func

33 Overall, these data suggest that smokeless tobacco elicits plasma exudation in the oral m

34 lth questionnaire revealed that he was using smokeless tobacco every day.

35 effects of cigarette smoke extract (CSE) and smokeless tobacco extract (STE) on cell survival and mot

36 Exposure to smokeless tobacco extract was associated with a signific

37 Smokeless tobacco extract-induced leaky site formation a

38 Indomethacin had no significant effects on smokeless tobacco extract-induced responses.

39 , therefore, were differentially affected by smokeless tobacco extracts in an organotypic tissue mode

40 In contrast, smokeless tobacco extracts promoted fibroblast growth at

41 shown that most consumers use cigarettes and smokeless tobacco for pharmacological purposes, includin

42 Use of smokeless tobacco in the United States has been relative

43 d of accelerating the decline in smoking and smokeless tobacco initiation.

44 dical school curricula, specific training in smokeless tobacco intervention, tobacco intervention tra

45 Smokeless tobacco is a powerful autonomic and hemodynami

46 Smokeless tobacco is associated with pathologic alterati

47 factor for periodontal disease, the role of smokeless tobacco is unclear.

48 The presence of oral smokeless tobacco lesions among adolescents may be an ea

49 Preventing smokeless tobacco lesions and their possible malignant t

50 Smokeless tobacco lesions were detected in 1.5% of stude

51 tronger risk factor than chewing tobacco for smokeless tobacco lesions, but the use of either of thes

52 cohol or cigarettes may increase the risk of smokeless tobacco lesions.

53 These results indicate that smokeless tobacco may also be an important risk factor f

54 arction (MI) in people who use snus, a moist smokeless tobacco product, we hypothesized that disconti

55 with regular and heavy nicotine intake from smokeless tobacco rather than from smoking.

56 Current users of smokeless tobacco should be informed of its harm and adv

57 A) asserted jurisdiction over cigarettes and smokeless tobacco under the Federal Food, Drug, and Cosm

58 co smoking (1.90 [1.38-2.62]; p<0.0001), and smokeless tobacco use (1.32 [1.03-1.69]; p=0.030) than i

59 ment for confounders, no association between smokeless tobacco use and all-cause (hazard ratio = 1.1,

60 ter understand the cancer risks of exclusive smokeless tobacco use and dual use of smokeless tobacco

61 Previous studies on smokeless tobacco use and head and neck cancer (HNC) hav

62 rvey was to evaluate the association between smokeless tobacco use and severe active periodontal dise

63 udy was to characterize the relation between smokeless tobacco use and the risk of all-cause and dise

64 Smokeless tobacco use appears to be associated with HNC,

65 e smoking, nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated wi

66 The pooled prevalence of current smokeless tobacco use in pregnant women was lowest in th

67 The health effects of smokeless tobacco use need further documentation.

68 The difference in smokeless tobacco use prevalence between HIV-positive an

69 7.8) for tobacco smoking, 3.4% (1.8-5.6) for smokeless tobacco use, and 27.1% (22.8-31.7) for any tob

70 1.9) for tobacco smoking, 2.1% (1.1-3.4) for smokeless tobacco use, and 3.6% (95% CI 2.3-5.2) for any

71 ative prevalence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately fo

72 luc), in urine and plasma after cessation of smokeless tobacco use, in which NNK is administered p.o.

73 d at intervals 2-126 days after cessation of smokeless tobacco use.

74 lity of borderline significance among female smokeless tobacco users (hazard ratio = 1.7, 95% CI: 1.0

75 eline (1971-1975) were categorized as either smokeless tobacco users (n = 1,068) or non-smokeless tob

76 r smokeless tobacco users (n = 1,068) or non-smokeless tobacco users (n = 5,737).

77 igarettes), based on the rates for exclusive smokeless tobacco users and exclusive smokers, was highe

78 ays after cessation than at baseline in both smokeless tobacco users and smokers, indicating stereose

79 Gluc (26.1 +/- 15.1 versus 39.6 +/- 26.0) in smokeless tobacco users and smokers.

80 3.89 +/- 2.43) were significantly shorter in smokeless tobacco users than in smokers.

81 The mortality experience of smokeless tobacco users was not significantly greater th

82 assessed the 20-year mortality experience of smokeless tobacco users.

83 the authors examined whether current use of smokeless tobacco was associated with increased incidenc

84 In conclusion, current use of smokeless tobacco was associated with increased risk of

85 Past use of smokeless tobacco was not associated with CVD incidence.

86 adults and never-smokers who currently used smokeless tobacco were twice as likely to have severe ac

87 lusive smokeless tobacco use and dual use of smokeless tobacco with other tobacco products, including

88 ion on bidis (small hand-rolled cigarettes), smokeless tobacco, and locally brewed alcohols.

89 s, pipe tobacco, hookah, snus pouches, other smokeless tobacco, dissolvable tobacco, bidis, and krete

90 te smoke may have more profound effects than smokeless tobacco.

91 f quitting which do not include switching to smokeless tobacco.

92 e acute hemodynamic and autonomic effects of smokeless tobacco.

93 sues, less is understood about the effect of smokeless tobacco.

94 r pipe smokers, and 2% were current users of smokeless tobacco.

95 All smokeless tobaccos stimulated keratinocyte proliferation

96 revalence of current tobacco use (smoked and smokeless) was estimated for every country.